Biocon Limited board approves QIP at ₹387.74 per share, with issue opening on 12 January 2026 and new oncology biosimilars announced.

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics Limited to 'BB+' from 'BB' and revised ...

Pharmaceutical stocks fell up to 9% on Friday, September 26, after US President Donald Trump announced a 100% tariff on branded and patented pharmaceuticals. Wockhardt led the losses, falling more ...

Nifty Pharma index declined 2.67% intraday on Friday after US President Donald Trump announced a 100% tariff on the sector with an exception for companies that have manufacturing capacity in the ...

Biocon’s arm Biocon Pharma has received approval from the US health regulator for its generic version of everolimus tablets for oral suspension used in the treatment of tuberous sclerosis complex, a ...